Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.03.2013 | letter to the editor

Duloxetine-induced life-threatening long QT syndrome

verfasst von: Matej Štuhec, PharmD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 5-6/2013

Einloggen, um Zugang zu erhalten

Excerpt

Duloxetine hydrochloride (DH) is a potent inhibitor of norepinephrine and serotonin reuptake, with low impact on dopamine uptake. In patients unresponsive to selective serotonin reuptake inhibitors, the administration of DH and bupropion (BUP) is an effective switching strategy [1]. …
Vorheriger Artikel Selenium intake and selenium blood levels: a novel food frequency questionnaire
Nächster Artikel MedUni Wien Researcher of the Month März 2013
Literatur
1.
Rosso G, Rigardetto S, Bogetto F, Maina G. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disorders. 2012;136:172–6.PubMedCrossRef
2.
Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005;27:1126–43.PubMedCrossRef
3.
Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharm. 2007;49:146–53.CrossRef
4.
Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:934–47.PubMedCrossRef
5.
Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother. 2003;37:999–1002.PubMedCrossRef
Metadaten
Titel
Duloxetine-induced life-threatening long QT syndrome
verfasst von
Matej Štuhec, PharmD
Publikationsdatum
01.03.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 5-6/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0330-6

Weitere Artikel der Ausgabe 5-6/2013

Ecarin modified rotational thrombelastometry: a point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban

  • short report

MedUni Wien Researcher of the Month März 2013

  • Researcher of the month March

Autologous stem cell transplantation in adults with metastatic sarcoma of the Ewing family: a single centre experience

  • original article

Female and male victims of violence in an urban emergency room—prevalence, sociodemographic characteristics, alcohol intake, and injury patterns

  • original article

Detection of Plasmodium sp.-infested Anopheles hyrcanus (Pallas 1771) (Diptera: Culicidae) in Austria, 2012

  • original article

Rapid prototyping technique in the preoperative planning for total hip arthroplasty with custom femoral components

  • original article